Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

The duality is a hallmark of Greater Boston’s lab market these days. Bright spots surely remain, such as big new lab ...

Basically, no folks, value investing is not dead. If anything, if you understand that financial strength and profitability ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

The Tobias and Lechleiter families donated $20 million to establish the Institute for Clinical Innovation at IU Health, the largest gift in its history.

The new diabetes company will be predominantly business-to-consumer, while Medtronic’s model was more business-to-business.

Antimicrobial-resistant (AMR) “superbugs” contribute to more than 4.5 million deaths globally per year and threaten to make ...